Patents Represented by Attorney, Agent or Law Firm B. Timothy Creagan
  • Patent number: 5635501
    Abstract: Compound of formula (I) or salts thereof wherein R.sup.1 is hydrogen, methoxy or formamido; R.sup.2 is an acyl group; CO.sub.2 R.sup.3 is a carboxy group or a carboxylate anion, or R.sup.3 is a readily removable carboxy protecting group or a pharmaceutically acceptable salt-forming group or in vivo hydrolysable ester group; R.sup.4 represents hydrogen or up to four substituents; X is S, SO, SO.sub.2 or CH.sub.2 ; Y is O, S, SO or SO.sub.2 ; n is 0 or 1; m is 1 or 2; and wherein in the (a) ring system the dotted line indicates that one pair of adjacent ring carbon atoms is joined by a C.dbd.C double bond. These compounds have antibacterial activity.
    Type: Grant
    Filed: January 25, 1995
    Date of Patent: June 3, 1997
    Assignee: Pfizer Inc.
    Inventors: George Burton, John H. Bateson, Richard L. Elliott, Stephen C. M. Fell
  • Patent number: 5624951
    Abstract: A compound of formula V: ##STR1## wherein all the R's groups are as defined in the specification, is useful in the treatment of bacterial infections.
    Type: Grant
    Filed: March 1, 1995
    Date of Patent: April 29, 1997
    Assignee: Pfizer Inc.
    Inventors: Bingwei Yang, Joyce Sutcliffe, Chris J. Dutton
  • Patent number: 5624929
    Abstract: Compounds of the formula ##STR1## wherein the broken line represents an optional double bond; X is O, S, CH.sub.2 or CH.sub.2 CH.sub.2 ; R.sup.1 is selected from the group consisting of hydrogen, halogen, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.6 alkanoyl, C.sub.1 -C.sub.6 alkyl, and C.sub.1 -C.sub.6 alkyl substituted with 1, 2 or 3 halogen atoms; R.sup.2 is selected from the group consisting of phenyl, substituted phenyl, heterocyclic groups, and substituted heterocyclic groups, said substituted phenyl and substituted heterocyclic groups being substituted with 1 or 2 substituents independently selected from the group consisting of C.sub.1 -C.sub.6 alkyl, trifuluoromethyl, and halogen; R.sup.3 and R.sup.4 are independently selected from the group consisting of hydrogen, halogen, C.sub.1 -C.sub.6 alkyl, or trifluoromethyl, or R.sup.3 and R.sup.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: April 29, 1997
    Assignee: Pfizer Inc.
    Inventors: Banavara L. Mylari, Joseph G. Lombardino, James M. McManus
  • Patent number: 5552387
    Abstract: An antibiotic of the formula ##STR1## wherein R is hydrogen or a pharmaceutically acceptable cation and Me is methyl.
    Type: Grant
    Filed: August 2, 1994
    Date of Patent: September 3, 1996
    Assignee: Pfizer Inc.
    Inventor: Edward A. Glazer
  • Patent number: 5514138
    Abstract: An improved device for repairing fractured bones is provided, the device comprising a specially designed connector, which is especially useful in combination with a plate having a tab cut out, a stop, a flat portion and a bore portion and with a compression screw and a lag screw.
    Type: Grant
    Filed: February 4, 1994
    Date of Patent: May 7, 1996
    Assignee: Pfizer Inc.
    Inventor: Thomas F. McCarthy
  • Patent number: 5502072
    Abstract: The present invention relates to novel substituted oxindoles of the formula I as defined below and related compounds, pharmaceutical compositions comprising such compounds, and the use of such compounds as inhibitors of phosphodiesterase ("PDE") type IV. The compounds of this invention are useful in the treatment of AIDS, asthma, rheumatoid arthritis, osteoarthritis, bronchitis, chronic obstructive airways disease, psoriasis, allergic rhinitis, atopic, dermatitis, shock, other inflammatory diseases, and other conditions where the action of phosphodiesterase type IV is implicated.
    Type: Grant
    Filed: November 26, 1993
    Date of Patent: March 26, 1996
    Assignee: Pfizer Inc.
    Inventor: Hiroko Masamune
  • Patent number: 5486527
    Abstract: Selective muscarinic receptor antagonists of formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are both optionally substituted phenyl, the broken line is an optional bond, X is >COH--, >SiOH-- or CH-- when the double bond is absent or is >C.dbd. when the double bond is present, X being attached to a carbon atom of A, A is selected from certain piperidine and pyrrolidine groups, n is 1 to 3 and R.sup.3 is optionally substituted phenyl or thienyl, pyridyl or pyrazinyl.
    Type: Grant
    Filed: July 28, 1994
    Date of Patent: January 23, 1996
    Assignee: Pfizer Inc.
    Inventors: David Alker, Peter E. Cross
  • Patent number: 5475005
    Abstract: Benzimidazole anthelmintic agents of the formula (I) and their non-toxic salts, wherein R.sup.1, which is in the 5(6)-position, is either H or certain stated substituents, "alk" is a methylene or ethylene group; R.sup.2 is cyano, C.sub.1 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, C.sub.2 -C.sub.4 alkanoyl, C.sub.1 -C.sub.4 alkoxy, C.sub.2 -C.sub.4 alkenoxy, aryl, heteroaryl, aryl-(C.sub.1 -C.sub.4 alkoxy) or heteroaryl-(C.sub.1 -C.sub.4 alkoxy), in which "aryl" means phenyl optionally substituted by 1 to 3 substituents each independently selected from halo, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkylsulphinyl, and C.sub.1 C.sub.4 alkylsulphonyl in which "heteroaryl" means thienyl, furyl or pyridininyl all optionally substituted by 1 to 3 substituents each independently selected from halo, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkylsulphinyl and C.sub.1 -C.sub.4 alkylsulphonyl; and R.sub.3 is a C.
    Type: Grant
    Filed: May 9, 1994
    Date of Patent: December 12, 1995
    Assignee: Pfizer Inc.
    Inventors: Bernard J. Banks, Christopher J. Dutton, Alexander C. Goudie
  • Patent number: 5461056
    Abstract: Racemic or optically active compound of the formula ##STR1## wherein X, Y, R.sup.1 and R.sup.2 are as defined above useful in the treatment of asthma or inflammatory airway or skin diseases.
    Type: Grant
    Filed: May 3, 1994
    Date of Patent: October 24, 1995
    Assignee: Pfizer Inc.
    Inventor: John B. Cheng
  • Patent number: 5430055
    Abstract: The culture ATCC 74256 and its mutants are capable of producing zaragozic acid A and other squalene synthase inhibitors.The compound of formula I herein may be prepared from culture ATCC 74256 and is useful in the treatment of fungal infections, and inhibition of squalene synthase, and protein farnesyltransferase.
    Type: Grant
    Filed: April 8, 1994
    Date of Patent: July 4, 1995
    Assignee: Pfizer Inc.
    Inventors: Thomas T. Dabrah, H. James Harwood, Jr., Liang H. Huang, Takushi Kaneko
  • Patent number: 5428043
    Abstract: Compounds of the formula ##STR1## wherein ring A, ring B, ring D, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6,R.sup.11, R.sup.12, R.sup.13, E, G, X and P are as defined below. The compounds of formula I are cholinesterase inhibitors and are useful in enhancing memory in patients suffering from dementia and Alzheimer's disease.
    Type: Grant
    Filed: October 29, 1992
    Date of Patent: June 27, 1995
    Assignee: Pfizer Inc.
    Inventor: Yuhpyng L. Chen
  • Patent number: 5418229
    Abstract: A compound of the formula ##STR1## wherein X, R.sup.1, R.sup.2, R.sup.3, R.sup..sup.4, Y, m and n are defined herein are useful as muscarinic receptor antagonists.
    Type: Grant
    Filed: May 31, 1994
    Date of Patent: May 23, 1995
    Inventors: David Alker, Peter E. Cross
  • Patent number: 5417923
    Abstract: An assay tray assembly and an assay tray primarily for chromatographic analysis has a plastics moulded test tray 1 mounted on a plastics moulded collection tray 72, The test tray has a spaced array of chambers 3 disposed as per a microtiter plate, Each chamber has a bottom outlet port 5 formed by a flange 8 which retains within the chamber a chromatographic medium to which test liquid deposited in the chamber is to be subjected for the percolate or eluate liquid to emerge from the respective outlet ports, The collection tray 72 has a spaced array of wells 16 disposed as per a microtiter plate to correspond with the chambers 3 and the tray 14 is mounted on the tray 72 for each chamber to communicate with a corresponding well 16. Each chamber 3 has a tubular spigot part 12 which extends into the respective well 16 to alleviate cross contamination of the liquid derived from the outlet ports 5.
    Type: Grant
    Filed: January 18, 1994
    Date of Patent: May 23, 1995
    Assignee: Pfizer Inc.
    Inventors: Dejan Bojanic, James R. Merson